Josephine van Dongen

3 Updated cost-effectiveness and risk-benefit analysis 55 care facilities 5 . Time series analyses have confirmed that these surveillance data correlate well with rotavirus disease activity in the population 15, 16 . Rotavirus surveillance data were used to scale the community incidence of rotavirus AGE as originally measured in 1999 (Sensor study 12 ) to the average for the years 2013–2016. We calculated the scaling factor as follows: 1 minus ([mean]annual rotavirus detections between 2013 and 2016/annual rotavirus detections in 1999).We kept the original rotavirus age distribution and the age-specific propor tion of cases visiting primary care, as no updated estimates were available. The scaled incidence estimates were applied to the 2016 population size to obtain the annual expected total number of community cases and GP visits; see Table 1 17 . Table 1. Parameters for model input Parameter Total popu- lation Non-tar- get group Target group Distribution Data source Method Bir th cohor t n (%) 171,387 157,847 (92.1%) 13,540 (7.9%) Fixed Statistics Netherlands 46, 47 Bir th cohor t size 2016. Prevalence of high-risk con- ditions, same as in Bruijning et al. 11 Rotavirus incidence Most likely value (minimum–maximum) Population: < 1 year 15,188 (10,161- 21,597) Calculated Per t Communi- ty-based co- hor t study 12 ; virologi-cal rotavirus surveillance data 5 Incidence based on simulations from original study data (for details see 17 ), scaled to the years 2013–2017. Distribu- tion among non-target and target groups based on relative size of each category in bir th cohor t Population: 1–4 years 35,756 (21,805- 54,972) Population: 5–14 yearsa 7897 (1426- 26,004)